Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

doi:10.1038/s41591-018-0053-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

Nature medicine - 1 Jun 2018

McDermott David F, Huseni Mahrukh A, Atkins Michael B, Motzer Robert J, Rini Brian I, Escudier Bernard, Fong Lawrence, Joseph Richard W, Pal Sumanta K, Reeves James A, Sznol Mario, Hainsworth John, Rathmell W Kimryn, Stadler Walter M, Hutson Thomas, Gore Martin E, Ravaud Alain, Bracarda Sergio, Suárez Cristina, Danielli Riccardo, Gruenwald Viktor, Choueiri Toni K, Nickles Dorothee, Jhunjhunwala Suchit, Piault-Louis Elisabeth, Thobhani Alpa, Qiu Jiaheng, Chen Daniel S, Hegde Priti S, Schiff Christina, Fine Gregg D, Powles Thomas

Abstract excerpt

We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Carcinoma, Renal Cell

Share to Kaplan-Meier Estimate

Share to Kidney Neoplasms

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 29867230
DOI: 10.1038/s41591-018-0053-3
PMCID: PMC6721896

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.PMID 29867230Read ↗

Myeloid–Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial CarcinomaSemantic proximity Read ↗

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.Semantic proximity Read ↗

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.Semantic proximity Read ↗

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.Semantic proximity Read ↗

Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulationSemantic proximity Read ↗

Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysisSemantic proximity Read ↗

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.Semantic proximity Read ↗

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialSemantic proximity Read ↗

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.